Synthetic biology: Ensuring the greatest global value

Systems and Synthetic Biology

Volumn 7, Issue 3, 2013, Pages 99-105

  Hollis, Aidan ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Health Impact Fund; Incentives; SynBio

Indexed keywords

EID: 84881542795     PISSN: 18725325     EISSN: 18725333     Source Type: Journal    
DOI: 10.1007/s11693-013-9115-5     Document Type: Article

References (20)

1. Cernuschi T, Furrer E, Schwalbe N, Jones A, Berndt E, McAdams S (2011) Advance market commitment for pneumococcal vaccines: putting theory into practice. Bull World Health Organ 89: 913-918.
2. Cohen-Kohler JC, Mrazek M, Hawkins L (2007) Corruption and pharmaceuticals: strengthening good governance to improve access. In Campos E, Pradhan S (eds) The many faces of corruption: tracking vulnerabilities at the sector level. Poverty Reduction and Economic Management, World Bank.
3. Economist (2012) "Tripped up".
4. Flynn S, Hollis A, Palmedo M (2009) An economic analysis of compulsory licensing for needed medicines. J Law Med Ethics 37(2): 184-208.
5. Hill S, Johnson K (2004) Emerging challenges and opportunities in drug registration and regulation in developing countries. DFID Health Systems Resource Centre.
6. Hollis A (2009) The Health Impact Fund and price determination, incentives for global health discussion paper no. 1.
7. Hollis A, Pogge T (2008) The Health Impact Fund: making medicines accessible for all. Incentives for global health.
8. Light D (2009) Advanced market commitments: current realities and alternate approaches. HAI Europe/Medico International, Amsterdam.
9. Moon S, Jambert E, Childs M, von Schoen-Angerer T (2011) A win-win solution? A critical analysis of tiered pricing to improve access to medicines in developing countries. Glob Health 7: 39.
10. Moran M, Guzman J, Ropars AL, Illmer A (2010) The role of product development partnerships in research and development for neglected diseases. Int Health 2: 114-122.
11. Ong HT (2006) Evidence-based prescribing of statins: a developing world perspective. PLoS Med 3(3): e50. doi: 10. 1371/journal. pmed. 0030050.
12. Presidential Commission for the Study of Bioethical Issues (2010) NEW DIRECTIONS-ethics of synthetic biology and emerging technologies.
13. Roin B (2009) Unpatentable drugs and the standards of patentability. Tex Law Rev 87: 503-570.
14. Syed T (2009) Should a prize system for pharmaceuticals require patent protection for eligibility? Incentives for global health discussion paper no. 2.
15. The Lancet (2012) Counterfeit drugs: a growing global threat. Lancet 379(9817): 685.
16. van Weely S, Leufkens HGM (2004) Background paper: orphan diseases. In: Kaplan W, Laing R (eds) Priority medicines for Europe and the world-a public health approach to innovation. World Health Organisation, Geneva.
17. World Health Organization (2006) Public health, innovation and intellectual property rights. Report of the Commission on Intellectual Property Rights, Innovation and Public Health, Geneva.
18. World Health Organization (2008) Resolution WHA59. 24, public health, innovation, essential health research and intellectual property rights: towards a global strategy and plan of action.
19. World Health Organization (2010) Research and development: coordination and financing. Report of the World Health Organization Expert Working Group on Research and Development Financing, Geneva.
20. World Health Organization (2012) Research and development to meet health needs in developing countries: strengthening global financing and coordination. Report of the Consultative Expert Working Group on Research and Development: Financing and Coordination, Geneva.